Hemostemix Inc.

Recent News

  • Hemostemix Announces HS 12 - 01 Clinical Trial Completion of Subjects' Follow-Up Visits at the End of March and Warrants Extended and Repriced

    Calgary, Alberta--(Newsfile Corp. - January 28, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce that all follow-up visits of the subjects enrolled in the HS 12 -01 clinical trial will be completed by March 31, 2021. A total 65 subjects who were enrolled in the trial, randomized 2:1 to receive ACP-01 or a placebo, will have completed the last follow-up appointments by March 31, 2021. The Company will provide additional information once...

    2021-01-28 9:23 AM EST
  • Hemostemix Announces the Bread Contract with the Department of Foreign Affairs, Trade & Development Canada

    Calgary, Alberta--(Newsfile Corp. - January 22, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXD) ("Hemostemix" or the "Company") is pleased to announce it has signed the Building Relationships Entrepreneurs & Dealmakers (BREAD) contract with the Department of Foreign Affairs, Trade and Development. An initiative to assist high-potential, biotech focused Canadian Small and Medium Enterprise (SMEs), the program is designed to accelerate the growth of Hemostemix and other Canadian biotechnology companies."We are actively working with the Trade Commissioner Service of...

    2021-01-22 9:15 AM EST
  • Hemostemix Announces Grant of Stock Options

    Calgary, Alberta--(Newsfile Corp. - January 4, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") announces that, in accordance with its stock option plan, it has granted on December 31, 2020, subject to regulatory approval, a total of 5,274,500 stock options to purchase common shares of ‎Hemostemix (the "Options") to directors, officers, employees and consultants of Hemostemix. Of the Options granted 3,887,100 vest immediately and 1,387,400 vest 50% immediately and 50% on December, 31 2021. All options...

    2021-01-04 8:00 AM EST
  • Hemostemix Announces Closing of Unit Private Placement

    Calgary, Alberta--(Newsfile Corp. - December 31, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") announces it has closed its previously announced non-brokered private placement of units ("Units") announced on December 18, 2020, for gross proceeds of $2,750,000 (the "Offering"). The Offering consisted of the issuance of an aggregate of 9,166,667 post -consolidated Units at a price of $0.30 per Unit. Each Unit consists of one post-consolidated common share in the capital of the...

    2020-12-31 9:06 AM EST
  • Hemostemix Announces Private Placement Update

    Calgary, Alberta--(Newsfile Corp. - December 29, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") announces that it was granted price protection of its previously announced non-brokered private placement of units ("Units") announced on December 18, 2020, for gross proceeds of up to $2,750,000 (the "Offering"). The Offering will consist of the issuance of an aggregate of up to 9,166,666 post rollback Units at a price of $0.30 per Unit. Each Unit consists of...

    2020-12-29 9:35 AM EST
  • Hemostemix Announces Corporate Update

    Calgary, Alberta--(Newsfile Corp. - December 23, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") The Company is pleased to announce that the previously disclosed proposed consolidation of the common shares of the Company on the basis of twenty pre-consolidation shares for one post-consolidation share (the "Consolidation") will take effect, subject to final acceptance by the TSX Venture Exchange, on or about December 30, 2020 under new CUSIP number 423694306. There will be no name change or...

    2020-12-23 11:05 PM EST
  • Hemostemix Announces Closing of Existing Private Placement and Announces a New Private Placement

    Calgary, Alberta--(Newsfile Corp. - December 18, 2020) -  Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") announces it has closed its previously announced non-brokered private placement of units ("Units") for gross proceeds of $1,272,117.04 (the "Offering"). The Offering consisted of the issuance of an aggregate of 127,211,704 Units at a price of $0.01 per Unit. Each Unit consists of one common share in the capital of the Company ("Common Share") and one common share purchase warrant ("Warrant"),...

    2020-12-18 4:01 PM EST
  • Hemostemix Files Its Unaudited Condensed Consolidated Interim Financial Statements and Management Discussion and Analysis for the Three Months Ended March 31, 2020

    Calgary, Alberta--(Newsfile Corp. - July 13, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") today filed on SEDAR its unaudited Condensed Consolidated Interim Financial Statements and Management Discussion and Analysis for the quarter ending March 31, 2020 and for the comparable period ending March 31, 2019.ABOUT HEMOSTEMIX Hemostemix is a publicly traded autologous stem cell therapy company. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01...

    2020-07-13 8:25 AM EDT